Dual Inhibition of EGFR With Afatinib and Cetuximab in the Treatment of Advanced Squamous Cell Cancers...
Squamous Cell Cancers of the Head and NeckThis is a single arm Phase II study for patients with recurrent or metastatic squamous cell carcinoma of the head and neck, who are previously treated with a platinum based regimen or with an immune checkpoint inhibitor. The primary objective is to evaluate the efficacy of the combination of cetuximab and afatinib.
Quality of Life After Primary TORS vs IMRT for Patients With Early-stage Oropharyngeal Squamous...
Oropharynx CancerOropharynx Squamous Cell Carcinoma20 moreOropharyngeal squamous cell carcinoma (OPSCC) is now the most frequently diagnosed head and neck cancer in Denmark which is mainly due to the increase of Human Papillomavirus (HPV). Patients with HPV-positive OPSCC have a significantly higher survival rate compared to HPV-negative OPSCC. The traditional primary treatment modality in Denmark is Intensity Modulated Radiation Therapy (IMRT), and in advanced stages in combination with chemotherapy. Since 2009, Transoral Robotic Surgery (TORS) has enabled surgeons to perform minimally invasive surgery as an alternative to standard radiotherapy treatment which is considered the primary treatment for OPSCC in many countries. There is a lack of randomised trials comparing long-term functional outcomes after TORS or IMRT. Current data are mostly derived from retrospective studies with selection bias. However, several small retrospective studies have shown promising results when comparing the two treatment modalities in favour of TORS with regards to treatment related swallowing function and quality of life (QoL) without compromising survival outcomes. This study aims to evaluate the early and long-term functional outcomes following two treatment arms 1) TORS combined with neck dissection and 2) IMRT±concurrent chemotherapy with a special focus on swallowing-related QoL.
Inhibition of Oral Tumorigenesis by Antitumor B
Squamous Cell Cancer of the Oral CavityThis is a randomized, double-blinded, placebo-control window of opportunity study of Anti-tumor B versus placebo. Anti-tumor B is a botanical agent composed of six Chinese herbs: Sophora tonkinensis, Polygonum bistorta, Prunella vulgaris, Sonchus brachyotus, Dictamnus dasycarpus, and Dioscorea bulbifera.
RFA to Prevent Metachronous Squamous Neoplasia Recurrence After Complete Endoscopic Submucosal Dissection...
Esophageal Squamous Cell NeoplasmEsophageal cancer is a highly lethal disease, and its incidence is still increasing in the world. Recent advances in image-enhanced techniques such as Lugol chromoendoscopy and narrow band imaging, the number of patients with early esophageal squamous cell neoplasias (ESCNs) detected has markedly increased. Endoscopic submucosal dissection (ESD) enables en bloc resection of the neoplasia, and the resected specimen allows for a pathological assessment to evaluate the curability. However, the patients who received complete ESD for early ESCNs frequently developed metachronous recurrence. The cumulative metachronous recurrence rate at 5 years was 50%, and the mean annual incidence of newly diagnosed metachronous tumors was 10%. Among them, those with "speckled" lugol staining pattern over the esophageal background mucosa have the highest risk and should be seen as a precancerous lesion of ESCCs. This issue is gaining attention in the era of endoscopic treatment, but currently there was no appropriate strategy to prevent the tumor recurrence in these high-risk subjects. Endoscopic radiofrequency ablation (RFA) is a rapidly evolving therapeutic modality, and recent studies have shown its efficacy and safety for eradicating for flat type early ESCNs. To search a best strategy for the prevention of ESCNs, the investigators thus propose a hypothesis that the preemptive RFA for esophageal "speckled" lugol background mucosa may prevent the metachronous neoplastic recurrence after complete endoscopic resection.
Cabozantinib in Combination With Cetuximab in Patients With Recurrent or Metastatic Head and Neck...
Head and Neck Squamous Cell CancerRecurrent Head and Neck Squamous Cell Cancer1 moreThe purpose of this study is to test the safety of cabozantinib, at different doses, in combination with cetuximab to find out what effects, if any, this combined treatment has on people with HNSCC.
Study of MEDI0562 Prior to Surgical Resection in Head and Neck Squamous Cell Carcinoma (HNSCC) or...
Head and Neck CancerHead and Neck Squamous Cell Carcinoma5 moreThis clinical trial will evaluate the safety and feasibility of a humanized OX40 agonist, MEDI0562, in the pre-operative setting for patients with head and neck squamous cell carcinoma or melanoma.
Toripalimab or Placebo With Paclitaxel and Cisplatin in Esophageal Squamous Cell Carcinoma
Advanced or Metastatic Esophageal Squamous Cell Cancer Without Previous Systemic ChemotherapyThis is one randomized, double-blind, multi-center, placebo-controlled phase III study. The objective of this study is to compare the effectiveness and safety of JS001 combined with paclitaxel and cisplatin(TP regimen )with placebo combined with TP regimen in patients with advanced or metastatic Esophageal Squamous Cell Carcinoma(ESCC )who have not received systemic chemotherapy previously. About 500 patients with advanced or metastatic ESCC who have not received chemotherapy previously will be enrolled in this study and 1:1 randomized into JS001 combined with TP group and placebo combined with TP group (i.e., 250 patients each in group A and B) The sample size was calculated based on the dual-endpoint of primary effectiveness endpoint (progression-free survival, PFS, as evaluated by BIRC per RECIST v1.1 criteria) and overall survival (OS). The hierarchical testing will be used for PFS and OS analysis at the overall significance level of two-sided 0.05, that is, all α levels (two-sided 0.05) will be firstly used for the hypothesis test of PFS; if the null hypothesis of PFS is rejected, the hypothesis test of OS will be performed at the two-sided significance level of 0.05. For PFS, it will be expected to observe 283 PFS events in 500 patients enrolled about 24 months after randomization of the first subject, thereby there is 85% statistical power to detect an improved PFS for JS001 in combination with TP versus placebo in combination with TP in subject with advanced or metastatic ESCC who had not previously received chemotherapy at the two-sided significance level of 0.05 (corresponding hazard ratio (HR) =0.7); for OS, it will be expected to observe 366 OS events in 500 patients enrolled about 39 months after randomization of the first subject, thereby there is 85% statistical power to detect an improved OS for JS001 in combination with TP versus placebo in combination with TP in subject with advanced or metastatic ESCC who had not previously received chemotherapy at the two-sided significance level of 0.05 (corresponding hazard ratio (HR) =0.73). It is planned to performed an interim analysis of OS at the time of PFS analysis (about 24 months after randomization of the first subject).
A Study of LGK974 in Patients With Malignancies Dependent on Wnt Ligands
Pancreatic CancerBRAF Mutant Colorectal Cancer6 moreThe primary purpose of this study is to find the recommended dose of LGK974 as a single agent and in combination with PDR001 that can be safely given to adult patients with selected solid malignancies that have progressed despite standard therapy or for which no effective standard therapy exists
OSI-774/Cisplatin/Taxotere in Head & Neck Squamous Cell Cancer
Head and Neck CancerThe goal of this clinical research study is to learn if giving the new drug, Tarceva® (OSI-774), in combination with Platinol® (cisplatin) and Taxotere® (docetaxel) is effective in the treatment of metastatic or recurrent head and neck cancer. The safety of this treatment will also be studied.
First Time in Human Study of AZD8701 With or Without Durvalumab in Participants With Advanced Solid...
Clear Cell Renal Cell CancerNon-Small-Cell Lung Cancer7 moreThe purpose of this study is to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Immunogenicity and Antitumor Activity of AZD8701 Alone and in Combination with Durvalumab (MEDI4736) in Adult Subjects with Select Advanced Solid Tumors